[HTML][HTML] The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients …
O Mulas, E Abruzzese, L Luciano, A Iurlo, I Attolico… - Annals of …, 2024 - Springer
Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …